Document Detail


Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
MedLine Citation:
PMID:  23210904     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Inhibitors of the phosphodiesterase enzyme PDE10A have been the target for extensive investigations and huge drug discovery research efforts during the recent years. Although PDE10A with its 13 years history is a relatively newly discovered target, it has been paradigmatic for the new generation of 'high efficiency drug discovery'. Several companies now have clinical programs aiming at validating the clinical potential of PDE10A inhibitors. The majority of companies have been focusing on the treatment of schizophrenia since preclinical evidence suggests that a PDE10A inhibitor could provide antipsychotic, pro-cognitive and negative symptom efficacy.
AREAS COVERED: This article highlights and reviews research advances published in the patent literature since mid-2009 until mid-2012. The article is supplemented with selected publications from the scientific literature, emphasizing the possible involvement of PDE10A inhibitors in the treatment of schizophrenia.
EXPERT OPINION: Several compounds from various companies are currently undergoing clinical testing, dominated by compounds in clinical Phase I. Focus is mainly on CNS diseases and schizophrenia is the leading target indication.
Authors:
Jan Kehler
Related Documents :
20848274 - The persecution of pharmacologists in nazi germany and austria.
24167344 - Biomarkers in schizophrenia: a brief conceptual consideration.
16308924 - Two chemists in two koreas.
14724914 - Franz boas, geographer, and the problem of disciplinary identity.
23270144 - Revisiting houston and memphis: the background histories behind the discovery of the in...
6533174 - Reactions to issues concerning sexual orientations, identities, preferences, and choices.
Publication Detail:
Type:  Journal Article; Review     Date:  2012-12-05
Journal Detail:
Title:  Expert opinion on therapeutic patents     Volume:  23     ISSN:  1744-7674     ISO Abbreviation:  Expert Opin Ther Pat     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-19     Completed Date:  2013-06-04     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9516419     Medline TA:  Expert Opin Ther Pat     Country:  England    
Other Details:
Languages:  eng     Pagination:  31-45     Citation Subset:  IM    
Affiliation:
Discovery Chemistry & DMPK, H. Lundbeck A/S, Valby, Denmark. jke@lundbeck.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antipsychotic Agents / pharmacology
Central Nervous System Diseases / drug therapy,  physiopathology
Cognition / drug effects
Drug Design*
Humans
Patents as Topic
Phosphodiesterase Inhibitors / pharmacology*
Phosphoric Diester Hydrolases / drug effects*
Schizophrenia / drug therapy,  physiopathology
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Phosphodiesterase Inhibitors; EC 3.1.4.-/PDE10A protein, human; EC 3.1.4.-/Phosphoric Diester Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prato Reaction of M3N@Ih-C80 (M = Sc, Lu, Y, Gd) with Reversible Thermal Isomerization.
Next Document:  Descriptive analysis of Iranian adolescents' stages of change for physical activity behavior.